Advanced search
Publication Cover
Scandinavian Journal of Infectious Diseases Volume 35, 2003 - Issue 8
Submit an article Journal homepage
45
Views
16
CrossRef citations to date
0
Altmetric
Research Article

Chronic Hepatitis C: Updated Swedish Consensus

Rune Wejstål
,
Annette Alaeus Unit of Infectious Diseases, Department of Medicine Karolinska Institutet, Karolinska Hospital Stockholm
,
Björn Fischler Department of Pediatrics, Karolinska Institutet Huddinge University Hospital Stockholm
,
Olle Reichard Unit of Infectious Diseases, Department of Medicine Karolinska Institutet, Karolinska Hospital Stockholm
,
Ingrid Uhnoo
&
Ola Weiland Division of Infectious Diseases, Karolinska Institutet Huddinge University Hospital Stockholm
Pages 445-451 | Published online: 08 Jul 2009

  • Wejstal R, Fischler B, Glaumann H, Norkrans G, Reichard O, Sonnerborg A, et al. Chronic hepatitis C – Swedish experts’ meeting recommends combination treatment. Scand J Infect Dis 2000; 32: 465–70.
  • Poynard T, Marcellin P, Lee S, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426–32.
  • McHutchison J, Gordon S, Schiff E, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485–92.
  • Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Schiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–65.
  • Fried MW, Schiffman ML, Reddy R, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975 /82.
  • Hadziyannis SJ, Cheinquer H, Morgan T, Diago M, Jensen DM, Sette H Jr, et al. Peginterferon alfa-2a (40kD) in combination with ribavirin in chronic hepatitis C: efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and ribavirin dose. J Hepatol 2002; 36\(Suppl 1): 1A.
  • Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am Surg Pathol 1995; 19: 1409–17.
  • Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. German Acute Hepatitis C Therapy Group. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452–7.
  • Davis G, Esteban R, Rustgi V, Hoefs J, Gordon S, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493–9.
  • Barbaro G, Di LG, Belloni G, Ferrari L, Paiano A, Del PP, et al. Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial. Am J Med 1999; 107: 112–8.
  • Cheng S, Bonis P, Lau J, Pham N, Wong J. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 2001; 33: 231–40.
  • Martin P, Mitra S, Farrington K, Martin NE, Modi MW Pegylated (40kDa) interferon alfa-2a (PEGASYS) is unaffected by renal impairment. Hepatology 2000; 32: 842.
  • Lamb MW, Marks IM, Modi MW, Preston RA, Pappas SC. Peginterferon alfa-2a (40kD) (PEGASYS) can be administered safely in patients with end-stage renal disease (Abstract). AASLD 52nd Annual Meeting, 10–13 November 2001, Dallas, USA.
  • Bruchfeld A, Ståhle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection–a pilot study. J Viral Hepatitis 2001; 8: 287–92.
  • Ferenci P, Shiffman ML, Fried MW, Sulkowski MS, Haeussinger D, Zarski J-P, et al. Early prediction of response to 40 kDa peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C (Abstract). AASLD 52nd Annual Meeting, 10–13 November 2001, Dallas, USA.
  • Jacobson KR, Murray K, Zellos A, Schwarz KB. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002; 34: 52–8.
  • Christensson B, Wiebe T, Åkesson A, Widell A. Interferon-α and ribavirin treatment of hepatitis C in children with malignancy in remission. Clin Infect Dis 2000; 30: 585–6.
  • Suoglu D, Elkabes B, Sokcu S, Saner G. Does interferon and ribavirin combination therapy increase the rate of treatment response in children with hepatitis C. J Pediatr Gastroenterol Nutr 2002; 34: 199–206.
  • Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Potzolu V, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24: 211–7.
  • Landau A, Batisse D, Piketty C, Duong van Huyen JP, Bloch F, Belec L, et al. Long-term efficacy of combination therapy with interferon-α2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001; 15: 2149–55.
  • Bruno R, Sacchi P, Filice G. Mitochondrial toxicity in HIV-HCV coinfection: It depends on the choice of antiretroviral drugs? Hepatology 2002; 35: 500–1.
  • Dodig M, Tavill AS. Hepatitis C and human immunodeficiency virus coinfections. J Clin Gastroenterol 2001; 33: 367–74.
  • Hinrichsen H, Benhamou Y, Reiser M, Sentjens R, Wedemeyer H, Calleja JL, et al. First report on the antiviral efficacy of BILN 2061, a novel oral HCV serine protease inhibitor, in patients with chronic hepatitis C genotype 1 (Abstract). AASLD 53rd Annual Meeting, 1–5 November 2002, Boston, USA.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.